[144] Century Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Century Therapeutics (IPSC) filing notifies a proposed sale under Rule 144 of 30,745 common shares with an aggregate market value of $17,521.58. The shares represent restricted stock that vested and were acquired on 08/15/2025 and the filer intends to sell on or about 08/18/2025 through Fidelity Brokerage Services on NASDAQ. The filing shows 86,389,098 shares outstanding for the issuer. It also discloses a prior sale by the same person of 475 shares on 06/09/2025 for $295.50. The acquisition payment is listed as compensation. The signer certifies no undisclosed material adverse information.

Positive

• Filer documents acquisition and sale details, including vesting date, acquisition method, broker, and intended sale date, demonstrating procedural compliance

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine insider sale from vested restricted stock; size is small relative to outstanding shares, so limited market impact.

The filing documents a planned Rule 144 disposition of 30,745 shares valued at $17,521.58, acquired via restricted stock vesting three days earlier and earmarked for sale through Fidelity on NASDAQ. Relative to the issuer's 86.39 million shares outstanding, the position represents roughly 0.036% of the float, indicating immaterial dilution or market pressure. The prior small sale (475 shares on 06/09/2025) shows occasional dispositions. From a financial perspective, this appears to be a routine insider liquidity event tied to compensation rather than a signal of company-specific distress.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 protocol; timing and recent vesting are documented, supporting compliance with insider-trading rules.

The notice clearly states that the securities were acquired by restricted stock vesting and that proceeds would be transacted pursuant to Rule 144. The signer affirms no material nonpublic information, and the use of a broker (Fidelity) is identified. These elements support procedural compliance with securities law and internal governance for executive compensation monetization. No unexplained transfers, related-party purchases, or unusual consideration terms are disclosed.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	30745	17521.58	86389098	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	Restricted Stock Vesting	Issuer			30745	08/15/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brent G. Pfeiffenberger 25 N 38th Street 11th Floor Philadelphia PA 19104	Common	06/09/2025	475	295.50

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does Century Therapeutics (IPSC) plan to sell under this Form 144?

The filer proposes to sell 30,745 common shares acquired via restricted stock vesting.

When were the shares acquired and when is the proposed sale date?

Shares were acquired on 08/15/2025 (restricted stock vesting) and the approximate sale date is 08/18/2025.

Through which broker and exchange will the IPSC shares be sold?

The filing lists Fidelity Brokerage Services LLC and the NASDAQ exchange.

How large is the proposed sale relative to Century Therapeutics' outstanding shares?

Proposed sale is 30,745 shares versus 86,389,098 shares outstanding (approximately 0.036%).

Has the filer sold any issuer shares recently?

Yes, the filer sold 475 shares on 06/09/2025 for $295.50.